FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169184564> ?p ?o ?g. }

• W3169184564 endingPage "e625" @default.
• W3169184564 startingPage "e613" @default.
• W3169184564 abstract "To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients.Retrospective cohort study with prospectively collected data between June 2011 and January 2019.Seventeen academic hospitals in the United States.We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups.None.We identified 281 patients (157 males) with a median age of 4.1 years (1.3-9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55-491.5 min] vs 62 min [33.3-120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5-1,255 min] vs 150 min [90-318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58-368 hr] vs 3 hr [1.4-5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5-40 d] vs [1.8-8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments.Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus." @default.
• W3169184564 created "2021-06-22" @default.
• W3169184564 creator A5001406846 @default.
• W3169184564 creator A5002880520 @default.
• W3169184564 creator A5002920691 @default.
• W3169184564 creator A5006482059 @default.
• W3169184564 creator A5013530465 @default.
• W3169184564 creator A5015601225 @default.
• W3169184564 creator A5020206810 @default.
• W3169184564 creator A5024218932 @default.
• W3169184564 creator A5024284175 @default.
• W3169184564 creator A5025520993 @default.
• W3169184564 creator A5031169469 @default.
• W3169184564 creator A5036362648 @default.
• W3169184564 creator A5036510142 @default.
• W3169184564 creator A5038504152 @default.
• W3169184564 creator A5038646029 @default.
• W3169184564 creator A5038960596 @default.
• W3169184564 creator A5039503181 @default.
• W3169184564 creator A5041308096 @default.
• W3169184564 creator A5046243217 @default.
• W3169184564 creator A5046645524 @default.
• W3169184564 creator A5059439153 @default.
• W3169184564 creator A5067808469 @default.
• W3169184564 creator A5068138814 @default.
• W3169184564 creator A5069812041 @default.
• W3169184564 creator A5069865243 @default.
• W3169184564 creator A5070411249 @default.
• W3169184564 creator A5074544711 @default.
• W3169184564 creator A5078339501 @default.
• W3169184564 creator A5079008341 @default.
• W3169184564 creator A5079982069 @default.
• W3169184564 creator A5080946525 @default.
• W3169184564 creator A5081537922 @default.
• W3169184564 creator A5084917629 @default.
• W3169184564 creator A5087567621 @default.
• W3169184564 creator A5090712549 @default.
• W3169184564 date "2021-06-14" @default.
• W3169184564 modified "2023-10-11" @default.
• W3169184564 title "Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study" @default.
• W3169184564 cites W1606313652 @default.
• W3169184564 cites W1803953876 @default.
• W3169184564 cites W1856414226 @default.
• W3169184564 cites W1859506634 @default.
• W3169184564 cites W1890247182 @default.
• W3169184564 cites W1920575800 @default.
• W3169184564 cites W1942678476 @default.
• W3169184564 cites W1965147078 @default.
• W3169184564 cites W1965796759 @default.
• W3169184564 cites W1972533790 @default.
• W3169184564 cites W1980045676 @default.
• W3169184564 cites W1984799539 @default.
• W3169184564 cites W1985828728 @default.
• W3169184564 cites W1988358928 @default.
• W3169184564 cites W1996528438 @default.
• W3169184564 cites W2000430902 @default.
• W3169184564 cites W2002406854 @default.
• W3169184564 cites W2015291905 @default.
• W3169184564 cites W2022981588 @default.
• W3169184564 cites W2029569324 @default.
• W3169184564 cites W2029710021 @default.
• W3169184564 cites W2039884834 @default.
• W3169184564 cites W2049338671 @default.
• W3169184564 cites W2065956573 @default.
• W3169184564 cites W2066575800 @default.
• W3169184564 cites W2070761513 @default.
• W3169184564 cites W2072014832 @default.
• W3169184564 cites W2072233814 @default.
• W3169184564 cites W2087918164 @default.
• W3169184564 cites W2089243066 @default.
• W3169184564 cites W2104806243 @default.
• W3169184564 cites W2109087679 @default.
• W3169184564 cites W2129118231 @default.
• W3169184564 cites W2129658473 @default.
• W3169184564 cites W2144996528 @default.
• W3169184564 cites W2150271239 @default.
• W3169184564 cites W2156680622 @default.
• W3169184564 cites W2161070714 @default.
• W3169184564 cites W2166904841 @default.
• W3169184564 cites W2167004406 @default.
• W3169184564 cites W2169749191 @default.
• W3169184564 cites W2170926970 @default.
• W3169184564 cites W2171218472 @default.
• W3169184564 cites W2198063087 @default.
• W3169184564 cites W2341467429 @default.
• W3169184564 cites W2429805485 @default.
• W3169184564 cites W2465450710 @default.
• W3169184564 cites W2494278506 @default.
• W3169184564 cites W2507804437 @default.
• W3169184564 cites W2508879024 @default.
• W3169184564 cites W2514656756 @default.
• W3169184564 cites W2601921236 @default.
• W3169184564 cites W2613284678 @default.
• W3169184564 cites W2730221123 @default.
• W3169184564 cites W2746155660 @default.
• W3169184564 cites W2751964669 @default.
• W3169184564 cites W2792850039 @default.
• W3169184564 cites W2865218412 @default.

• next